首页> 外文期刊>Neurosurgery >Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage.
【24h】

Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage.

机译:蛛网膜下腔出血后脑脊液和血浆中的凝血和纤溶激活。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Intrathecal fibrinolytic therapy has been used as one of the anticerebral vasospasm (VS) preventative therapies in patients with subarachnoid hemorrhage (SAH). However, the changes in coagulation and fibrinolysis in the blood and cerebrospinal fluid (CSF) after SAH remain unknown. METHODS: Fifty patients with SAH caused by ruptured cerebral aneurysms were studied postoperatively to detect the serial changes of the thrombin-antithrombin III complex, active plasminogen activator inhibitor (PAI)-1, and tissue plasminogen activator (tPA)-PAI complex (tPA-PAI) activities in the plasma and CSF collected from cisternal drainage catheters. RESULTS: The CSF levels of all parameters and plasma PAI-1 levels were significantly higher in patients with severe SAH than in those with mild SAH. There was no relationship between the CSF and plasma levels of these parameters (except the CSF levels of tPA-PAI) and the initial neurological statuses. The CSF PAI-1 levels increased to greater than 20 ng/ml near the time of the occurrence of cerebral VS, whereas they remained below 20 ng/ml in patients without VS. The CSF tPA-PAI levels showed the highest peak near the time of VS remission. The CSF PAI-1 and tPA-PAI levels were significantly lower in patients with good outcomes than in those with poor outcomes. CONCLUSION: Both the coagulative and fibrinolytic systems were activated in the CSF and plasma after SAH in correlating to the amount of SAH clot. The intrathecal administration of fibrinolytic agents should be started early after surgery, before CSF PAI-1 levels increase, for patients with severe SAH. Patients with CSF PAI-1 levels greater than 20 ng/ml experienced high incidence of VS and poor outcomes.
机译:目的:鞘内纤维蛋白溶解疗法已被用作蛛网膜下腔出血(SAH)患者的抗脑血管痉挛(VS)预防疗法之一。但是,SAH后血液和脑脊液(CSF)中凝血和纤维蛋白溶解的变化仍然未知。方法:对50例脑动脉瘤破裂引起的SAH患者进行了术后检查,以检测凝血酶-抗凝血酶III复合物,活性纤溶酶原激活物抑制剂(PAI)-1和组织纤溶酶原激活物(tPA)-PAI复合物(tPA-从脑池引流管收集的血浆和CSF中的PAI)活动。结果:重度SAH患者的所有参数的CSF水平和血浆PAI-1水平均显着高于轻度SAH患者。这些参数的脑脊液和血浆水平(tPA-PAI的脑脊液水平除外)与初始神经系统状态之间没有关系。在发生脑VS时,CSF PAI-1水平升高至大于20 ng / ml,而在没有VS的患者中,CSF PAI-1水平保持在20 ng / ml以下。 CSF tPA-PAI水平在VS缓解时显示最高峰。结果良好的患者的CSF PAI-1和tPA-PAI水平显着低于结果差的患者。结论:SAH后脑脊液和血浆中的凝血和纤溶系统均被激活,这与SAH凝块的数量有关。对于严重SAH的患者,应在术后早期,CSF PAI-1水平升高之前开始鞘内施用纤溶剂。 CSF PAI-1水平大于20 ng / ml的患者发生VS的发生率高且预后差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号